Lumos Diagnostics (ASX:LDX) has signed an agreement with Henry Schein Medical for the FebriDx point-of-care test.
The agreement expands Henry Schein’s distribution of FebriDx to include Spain and Portugal.
FebriDx is a rapid point of care (POC) test to differentiate a viral from a bacterial acute respiratory infection. It produces results in ten minutes from fingerstick blood. It can help rapidly and accurately manage infectious patients in primary care, urgent care, emergency department, paediatric and other outpatient settings.
Henry Schein’s Medical will sell the FebriDx test throughout Spain and Portugal, with sales and marketing activities commencing immediately.
“We are delighted to expand our distribution of FebriDx beyond the UK and into Spain and Portugal,” said Rick Corstanje, the general manager of Henry Schein Medical in Spain and Portugal.
“At Henry Schein, our goal is to help health care professionals enhance efficiencies so they can focus on delivering quality care.” “It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics.
“Henry Schein has been a terrific and supportive partner for Lumos in the UK, despite the headwinds the pandemic generated for products such as FebriDx. With our recent US clearance and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, and further refining our US and global sales strategy. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the European market.”
